Bacteriophages
Why in News?
- Bacteriophages are in the news in August 2026 after researchers from Stanford University and the Arc Institute demonstrated that AI can design functional bacteriophage genomes that do not exist in nature. The study generated novel phages capable of infecting and killing E. coli, opening new possibilities for combating antimicrobial resistance (AMR).
- The development is significant because bacteriophages are being explored as precision alternatives or complements to antibiotics, particularly against multidrug-resistant bacteria.
- Bacteriophages (phages) are viruses that specifically infect bacteria; they attach to bacterial cells, inject their genetic material and use the bacterial machinery to produce new phages, eventually destroying the host cell in the lytic cycle.
- Unlike broad-spectrum antibiotics, phages can be highly specific to particular bacterial species or strains, potentially preserving beneficial microbiota.
- Researchers used AI-based genome-language models to design completely new bacteriophage genomes and synthesised selected candidates in the laboratory.
- 16 AI-designed phages were found to be functional, successfully infecting and killing E. coli.
- The breakthrough demonstrates how AI can learn evolutionary constraints in viral genomes and generate viable biological sequences, potentially accelerating the discovery of therapeutic phages.
- It also raises important questions regarding biosafety, regulation and responsible use of AI in biological design.
- Phage therapy uses bacteriophages to treat bacterial infections and has gained renewed attention because antimicrobial resistance is reducing the effectiveness of conventional antibiotics.
- Phages may be used alone or in combination with antibiotics; recent clinical research has reported successful combined phage–antibiotic treatment in difficult bacterial infections.
- A major advantage is specificity, while a major limitation is that a phage effective against one bacterial strain may not work against another, requiring susceptibility testing and sometimes phage cocktails.
- India faces a substantial AMR burden, making alternative antimicrobial strategies such as phage therapy scientifically and strategically relevant.
- Historically, India has also had a connection with phage research: Felix d’Herelle's work at the Haffkine Institute, Mumbai, contributed to early phage-therapy research in India.
- However, clinical translation requires stronger regulatory frameworks, standardisation, genome sequencing, manufacturing capacity and clinical evidence.
- High specificity: A phage may target only particular bacterial strains.
- Bacterial resistance: Bacteria can evolve mechanisms to evade phages.
- Regulation: Personalised and rapidly evolving phage preparations create challenges for conventional drug-approval systems.
- Biosecurity: AI-generated biological entities raise concerns about dual-use research and misuse.
